Markets Shrug Off Semi Weakness…And One Biopharma Stock Surges After Trial Results 6/24/24

24 Jun 2024 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Summary: CNBC's "Fast Money" - Episode: Markets Shrug Off Semi Weakness…And One Biopharma Stock Surges After Trial Results (6/24/24)

Episode Overview In this episode, hosted by Melissa Lee, the panel of expert traders discusses the recent performance of the semiconductor market, particularly the decline of Nvidia, and the rise of biotech stock Alnylam Pharmaceuticals following promising trial results for a heart disease medication.

Key Topics Discussed

Nvidia's Decline

  • Recent Performance: Nvidia's stock dropped nearly 7%, marking its largest decline since mid-April and a 16% drop from its record high set just a week prior.
  • Market Impact: Despite Nvidia's losses, the broader market (Dow +260 points) seemed unaffected, indicating a potential decoupling of Nvidia's performance from the overall market trend.
  • Expert Opinions: The traders speculated whether Nvidia's downturn could lead to a broader market correction, with some suggesting that other tech stocks might follow suit if Nvidia's struggles persist.

Broader Market Sentiment

  • Sector Rotation: The discussion covered how sectors such as energy and utilities were gaining traction while technology stocks faced turbulence.
  • Investor Confidence: There was discussion around whether the current market levels are sustainable or if a correction is imminent, especially with the upcoming election cycle on the horizon.

Alnylam Pharmaceuticals Surge

  • Trial Results: Alnylam's stock surged nearly 35% after late-stage trial results demonstrated significant efficacy for its heart disease drug, potentially making it the new standard of care.
  • CEO Insights: An exclusive interview with CEO Yvonne Greenstreet highlighted the promising data and future plans for regulatory submission and market launch.

Bank Sector Developments

  • Fed's Capital Overhaul: The panel also discussed the implications of a less stringent capital requirement for banks, which could bolster the sector’s performance.
  • Market Reactions: Despite ongoing caution around the consumer's financial health, there were signs of stability in bank stocks amid this news.

Currency and International Markets

  • Japanese Yen Weakness: The yen fell to its lowest level against the dollar in years, prompting discussions about potential interventions by the Bank of Japan (BOJ) and the implications for Japanese equities.
  • Investment Outlook: Experts weighed in on how currency fluctuations and central bank policies might affect U.S. multinational companies and their earnings.

Retail Sector Insights

  • Walmart vs. Target: The traders discussed recent performances of major retailers. Walmart reached an all-time high, while Target sought to rejuvenate its brand through a partnership with Shopify.

Key Takeaways

  • Tech Sector Vulnerability: Nvidia's decline raises concerns about the strength of the tech sector and its influence on the broader market.
  • Biotech Opportunities: Alnylam's success illustrates potential growth areas within the biotech industry, particularly in treatments for chronic diseases.
  • Bank Stability and Regulations: Easing regulatory pressures on banks could lead to improved performance and investor confidence moving forward.
  • Currency Dynamics: The yen's weakness and its implications for international trade and U.S. corporations highlight the interconnectedness of global markets.

Conclusion This episode of "Fast Money" provides a comprehensive overview of current market trends, highlighting the interplay between technology, biotech, and retail sectors, as well as the broader economic indicators that could influence investor strategies going forward. The discussions emphasize the importance of ongoing market analysis and understanding sector dynamics in navigating investment decisions.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:03Live from the Nasdaq market site in the heart of New York City's Times Square. This is Fast Money. Here's what's on tap tonight. Decoupled shares of NVIDIA sinking again, erasing more than two weeks of gains. But surprisingly, the broader market holding up as energy and utilities move higher. So does this put an end to the argument? So goes NVIDIA. So goes the market. Plus, a Boeing bounce shares rising even as the government reportedly urges the DOJ to bring criminal charges against the aerospace giant. So has all the bad news been baked into the stock? And later, shares of Anilum Pharmaceuticals soaring to levels not seen in over a year after late-stage trial results for heart disease medication.

0:38CEO Yvonne Greenstreet will join us for an exclusive interview to talk about the drug and what this all means for the company. I'm Melissa Lee, come to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Dan Nathan, Guy Adami, and Savita Subramanian, head of U.S. Equity and Quantitative Strategy at Bank of America Securities. Welcome, Savita. Thank you. And we start off with a third day of massive losses for NVIDIA. The semi stock sliding almost 7 percent today. Its biggest drop since mid-April, its worst three day decline since December 2022. It is now down 16 percent from the record high hit just last Thursday, shedding nearly a half a trillion dollars in market cap in that time.

1:17Today's move dragging down the rest of the chip sector, Marvell Technology, Qualcomm, Broadcom, Taiwan Semi all seeing outsized losses. But the rest of Wall Street seemed to shrug off this weakness. The Dow gaining more than 260 points while the S &P 500 closed around the flat line. So this fear we had that the break in NVIDIA would take that down the entire market, is that turning out to not be the case, Guy? One day does not a trend make, Melissa, as you know. But we flagged this last week, that reversal. We talked about how it looked like something we saw in March. And it took about a month-ish for the broader market to then subsequently catch up to the move to the downside in NVIDIA.

1:55Frankly, I think it'll be a little quicker this time. And to your point, I mean, it's 16 percent-ish over the last few trading sessions, probably a little more room to the downside. You know, the market's going to start to catch up. Now, the S &P, as you mentioned, not a big day. Obviously, the Dow was a reversal of the entire thing, and there is a rotation. But at some point, you know, if you continue to see the weakness in NVIDIA and the subsequent 10, you know, the NVIDIA, what's the word I'm looking for? Adjacent trades. Adjacent, like Dow. It's going to have an impact on the S &P without question.

2:23But that's a really important point. I mean, Dell's down 20 % from its recent highs. Another name that we were tracking pretty closely, Supermicro. You remember that one? It kind of made it out of the small caps and got into the large caps in a very short period of time. I don't think I've ever seen that in my career where we've seen that sort of move that quickly. That stock's down about 25%. It never even got near its prior highs from March, that sort of thing. And, you know, so some of these adjacent names are not acting particularly well. I think a lot of enterprise software acts really poorly.

2:50I think there's some consumer internet that acts badly. FinTech acts really badly. So I just feel like if you think about the customer concentration that NVIDIA has, 40 % of their sales come from some of these biggest AI sort of names. If you're thinking about it, it's Google, it's Amazon, it's Meta, and it's Microsoft. At some point, those names will continue or they will play catch up to NVIDIA if it continues to go lower. Are you worried about the rest of the market rolling over? Not worried. I mean, I think one of the reasons we're at 5 ,400. That's our target, which is a little bit lower than where the market is here.

3:22And the reason we're not raising our target is it feels like this is a pretty healthy level. I think there could be a little bit of a shakeout, a broadening of the market, but some give back and, you know, mega cap tech. I think what's happening right now is interesting because we're heading into quarter end, the first half. We're moving into a very potentially volatile period with the election coming up. I think that part of what we're seeing now is just taking in bets, kind of neutralizing exposure. and that's where you see some of these crowded momentum winners, you know, maybe give back a little bit.

3:56I mean, the average target on the street is somewhere around where you are. So maybe that is that maybe people are expecting that this level is healthy. And you know what? Time to lock in some gains. Yeah, I think there was a poll done with over 560 strategist market participants where 5600 is right where people are. Everything you announced coming into the show, everything we're going around the table about, you're talking about the market, not talking about NVIDIA, is great for the market. Let's be clear. I don't hear anything here that's a problem. In fact, narrowing breadth in a rising market is what we should be fearful of.

4:25And if you see the rotation today, why isn't a day when you had rotation into banks and energy a great day? And so when you've had a 15 percent move or a 16 percent move on an intraday high on Thursday and NVIDIA and it's come back, I mean, like it had to. So I just, you know, I look at the dynamic where before that move, I probably said on that show Wednesday or Thursday or Tuesday last week, the Dow has underperformed the S &P by 1400 basis points this year. And by the way, it's an S &P that had two thirds of its return profile coming from a video. It's not really quite, but the math is in terms of the waiting and the move and you can kind of extract it out.

5:01And that's where you get to. So I realize that markets have had a good run. The more important dynamic is that the S &P is up almost 11 percent from from April 19th. Like that's the one that should have people a little bit like, hey, you know, S &P shouldn't be doing this, even though the Nasdaq, the top six, not even the adjacent. But we're talking about everybody other than Tesla. So the magnificent six is 40 percent of the Nasdaq. So, Dan, by the way, welcome back. Well, thank you. Where was he? He was abroad in Europe. And now he's a dude. No, he went to another bunch of companies. I was a Taylor Swift.

5:33I'm a Swiftie. Swifty. Why aren't you happier that the market is brought? Why can't you just be happy for what we have, Dan? It's fine. Well, the Russell 2000 can't get out of its own way. Regional banks can't get out of their own way. I think the IYT guys brought this up. So we're talking about the transports have never confirmed the new highs in the S &P 500. You know, the Nasdaq, to Tim's point, outperformed from the April lows. It was up 17 percent, the Nasdaq composite versus the S &P that was up about 10, 11 percent. So we've seen that massive outperformance. The other thing I'll just say is that when we got into quarter end Q1, you know, we saw a pullback into the April lows, about 6 % in the S &P 500.

6:11When that happened, NVIDIA went down 23%. Think about how much higher NVIDIA is right now. Think about how much higher that Fab Five is right now. So Tim's talking about a narrowing and then this breadth. But energy stocks, they had a good couple days here. They don't act well. Well, it's one day. So I'm not even here to tell you that breadth is back. I'm here to tell you today, if we're looking at the market saying, oh, boy, what happened to the market today? Well, there's a couple of things that happened that if they continue, I don't think are bad at all. I think banks, energy and utilities should be having they should participate.

6:40I am overweight those places relative to their market weightings for my clients and also just outright, because I think the valuations, those are places where I think we can defend what's going on. Well, I'm going to get into your head for a little while and it's kind of roomy. But I would posit that maybe the reversal that we saw at NVIDIA, it's not just a pullback from highs, but it was the way they pulled back. And it was Broadcom and NVIDIA, the two leaders in the AI chip sector, that did the same thing on extremely heavy volume. Hit a record high, then pulled back and closed basically at the lows of the session.

7:14Yeah, and we mentioned that last week. Karen's point was the NVIDIA move just got us back to where we were a few days earlier. And technically, she's right, but it's the way you get there, right? When you see reversals or engulfing patterns, whatever you want to call it, of the magnitude that we've seen now in NVIDIA's case twice in the last few months, you have to take notice. And as I said earlier, it took a while for the broader market to catch up, but it wound up catching up in a pretty meaningful way by the middle of April. I think it's going to be faster this time, and maybe that is a healthy thing.

7:43But again, you've got to watch because banks alone and energy alone, they cannot nearly make up for the ground that you could potentially lose in a tech trade. If you are a believer in a rotation of sorts, Savita, where would you put your money if you pull it out of tech? I love banks. I love energy. My favorite size and style box, this is where I have super high conviction, large cap value. This is where I think we want to go. This is going to start to work in the second half of this year, which is essentially now. And I think that there's an argument to be made that banks and energy in that large cap space are the new high quality areas of the market that actually have, you know, supply discipline.

8:29Banks are de-levered. They're the only lending channel left around after the regionals and private equity and private credit have extended all the loans. So I feel like this is the beginning of a trend where large cap value, dividend yield, kind of all the stuff that worked today is going to kick in and continue to lead the market. And I have a lot of different reasons for this, which hopefully we can talk about as the show progresses. But that is my highest conviction call. So I obviously think the same thing and just pointed that out. But is that what happens when you have a market top? because if you think about these, the weightings of the sectors we're talking about, they're inconsequential on some level.

9:09I mean, energy is 4 % of the S &P. I think it should be 10, but probably not in the next five years will it be. You know, and even though it was 16 back at its peak. So agree that low PE stocks, I read your work. We always all read your work. It's great that they tend to outperform over time. But if you think about some of this outperformance has coincided with market peaks. And again, the way the markets are structured. I don't think we're at a peak though. I mean, I think that maybe we see a little bit of a correction, but, you know, all of the things that typically happen before the market peaks haven't necessarily happened this time around.

9:43We haven't seen, you know, consumer confidence get to those super crescendo-like levels. We haven't seen positioning get really aggressive. We haven't seen, I mean, we've seen some signs. momentum feels a little bit toppy, but I don't necessarily feel like all that money has gone straight into equities and it's over. Yeah, it's funny. As you mentioned, large cap value. Okay. There's not a lot of large cap value out there. When you think about it, pharma doesn't look particularly value-ish. If you're looking at like an Eli Lilly, it's definitely at the heels of a huge mega trend. But I look at banks, I got to go back to April 12th.

10:19Okay. When JP Morgan reported their Q1 results. That stock went down 6.5%. Jamie Dimon, right, the anointed one, was very cautious about the consumer. You just mentioned, you know, not so cautious, but they were cautious about a lot of things going on. That stock gapped down 6.5%, filled in that gap pretty quickly, and now it's higher. But I wonder what's going to happen when we get to two weeks from now or whatever it is, and we start hearing from some of the big banks. You know, I don't know. It doesn't feel particularly great right here, right now, especially where valuations are. Well, you know, Some of the banks are more expensive and some are cheaper, and I guess I would go for the cheaper ones.

10:55But I think that we've heard this caution around the consumer story for a really long time. The consumer is right on the precipice of breaking every week, and there's a new story about why the consumer is weakening. Meanwhile, delinquencies are just starting to tick up from all-time low levels, right? Right. I mean, when you look at the charts, the consumer looks like they're getting a tiny bit less healthy, but from incredibly healthy levels. So I look at data around the consumer moderating and I think, OK, this is just coming off of those COVID highs and things are actually pretty good. I mean, consumers are maybe shifting from services to goods or, you know, maybe like buying fewer boats, selling their boats that they bought during COVID.

11:39You're buying fewer boats these days. I don't have a boat, Tim. I mean, cutting back on the boats, guy. No, you got to cut back on your boat. Well, I mean, now that you've taken me down this road, there's a saying, the two best days in a boat owner's life are the day they buy the boat and the day they get rid of it. Just so we're on the same page. The more you know. Play that graphic. But large cap value. Exxon Mobil's half a trillion dollar company trades at a 15 multiple. Chevron,$300 billion company trades less. So energy is still the place to be. All right. Let's stick with banks here. Developing story for the sector.

12:10The stock's getting a bump today with both the money centers and regionals jumping more than 2 percent. This amid reports that the Fed's bank capital overhaul would be significantly less onerous to lenders than expected. According to Reuters calculations, regulators would require banks to increase the amount of capital they hold in case of emergency by 5 percent rather than the 16 percent originally expected. The Fed telling our Steve Leesman it hasn't made any decisions on timing, process or substance of the new rules and that it's not targeting a specific range. But we did see a lift midday on these headlines crossing.

12:42And obviously, that would be a good thing for the sector. You so love, Savita. Absolutely. I mean, I think even, you know, the yield curve steepening, banks getting a little loan growth. This is all a good, good period. Look, banks have had a target on their back really since the great financial crisis. I'm not saying it's off and I'm not saying it wasn't deserved. I mean, there's no question that too big to fail for a reason. But if you think about the balance sheets here and how they have been buffered and the dynamic of capital giveback, I think is very important. But I think it translates into the multiple that banks are going to be able to trade at.

13:16So I also think about Citibank, which is probably the cheapest of the money center banks, a bank on long. The services dynamic of their business and the growth that you're seeing is part of where that bank is re-rating. And so cost from AI and all that year of efficiency and savings that other people are getting, they're getting a little credit for. But the services business is really important. Cities trading$61. Book value is$99. 80%. I can't even do that math. It's an$80 stock. And we've said that for a while. So there's certain banks that are still cheap right here. All right. Meantime, the Japanese yen touching its lowest level against the dollar since late April.

13:50Trading near 160. It's hovering near its lowest levels in over 30 years. Let's bring in BK Asset Management's Kathy Lean for more. Kathy, 160 is like the line in the sand, 160, 165. And so do you think that the BOJ will actually step in? I think they're going to have to. I think that, you know, if traders take it above the April high and we don't see any evidence of the Japanese government coming in, they're going to push it even higher. The real question, Melissa, is whether it's going to work, because we saw how the charts moved in April and the intervention was very short-lived. I mean, I almost feel like it's a foregone conclusion that it won't work.

14:28I mean, when has intervention actually worked? And so how do you trade that with the knowledge that they'll probably step in and it probably won't work? Well, as traders, it's very dangerous to be holding any type of short yen position at these levels. If you are short yen, it must be very small positions. And I think, you know, even if you have stops, they're going to be slipped incredibly. So the best bet is probably when you have intervention to ride that wave for a very short term move. But usually, you know, within a five day period, the intervention effects tend to fade. So you could also wait it out, wait for the initial volatility to settle and then get back in, knowing that nothing has really changed for Japan.

15:07Kathy, how much of this, Tim, thanks for joining us. How much of the recent move do you think gets back to central bank differentials? Because I don't I don't think a lot of the move over the last, say, call it back six months for the previous two years was necessarily central bank differentials, even though we know the Fed's been aggressive. The BOJ, certainly the conversation is on a relative basis to where they've been. You know, you can make an argument that the BOG, the delta there on their hawkishness was even more than the Fed. But obviously, with the Fed pulling back on cuts this year, the sense that the Fed is maybe the most hawkish of the major global central banks.

15:41Do you think that's an issue? Because it hasn't seemingly historically been the issue with the yen carry trade. I think it's absolutely been an issue. I think that the dollar is strong and that is what's driving up dollar yen. The market shifted dramatically after the last dot plot came out. And at the end of the day, even though the VOJ may be more hawkish on a relative perspective than the Fed, interest rates in Japan are next to nothing compared to more than five percent rate in the U.S. So they're going to need to do a lot more work to keep those funds domestic in Japan. And I think that's one of the most serious problems.

16:14There's another meeting in July, Kathy, and I'm wondering if you think that BOJ will punt bond buying further down the road or if they'll actually engage or give us an outline. I think that they are going to engage in the bond buying changes. But the question the market really is looking for is whether that's going to be accompanied with a rate hike, because we really need that one-two punch to kind of carve out a bottom in the Japanese yen. I think that, you know, right now the market's still very uncertain with whether we're going to get that interest rate hike if they do change their bond buys.

16:48And I think it's part of the reason why the yen remains so weak. Kathy, what level do they start talking about a currency crisis? Because I think it's happening in slow motion. Well, I mean, at the end of the day, they focus more on volatility than the currency level itself, right? So right now, volatility in one month implied options are still significantly lower than where they were in April when they came into the market. So they told us they don't target the currency. They focus more on volatility. But it would have to say that above 165 is where it really becomes trouble. Kathy, great to see you.

17:18Thank you. Thank you. Kathy Lean. So what does this do to your outlook for Japanese stocks? It makes me want to buy gold, first of all. I think Japanese stocks, especially the banks, would struggle under a lower yen environment for sure, especially if you look at Tokyo Mitsubishi Bank, where I think the kind of the export dynamic of this bank is actually really done very well with a weaker yen. I look at Japanese equities on valuation. They're trading it a little under 15 times historically in line, but relative to the current dynamic. No, very cheap, much better corporate governance, a lot of upward pressure from the regulators to have Japanese companies pay back more free cash flow.

17:57So I stayed long Japanese equities. Yeah, I'd just say for U.S. multinationals, though, the strength that we've seen in the dollar, despite that we've seen yields come in 50 basis points over the last few weeks, is kind of interesting. So I wonder if we're going to start hearing that a little bit. I get it year on year. It's probably unchanged a little bit. But if Guy's talking about a currency crisis in Japan, it'll be interesting to see the dollar strength, where that kind of permeates to outside of Japan. Yeah, I mean, I think if you look at earnings, periods of dollar strength, especially relative to the euro, which is probably the most relevant currency for the U.S., are not great for earnings.

18:29So, you know, just that currency translation impact alone could be a hit to earnings going forward. I do think, though, that the U.S. has become a little bit more insulated just by, you know, becoming more inward focused and reshoring. So maybe that dollar math doesn't work the same way it did, you know, prior to the Trump tariffs in 2018 and beginnings of deglobalization. I think that's that's kind of an interesting theme that might might play out a little bit more over time. It's been interesting to see. I mean, the intervention worked for like a month, maybe. And now here we are approaching those levels again.

19:06And they have a problem there, whether they acknowledge it or not. I mean, they raise rates, their currency weakens. That's not good. And the people within the shores of Japan cannot be happy with how their economy is acting right now. So I don't think enough people are talking about it. Through 160, more people will. Coming up, Boeing's fate on the clock. The DOJ deciding whether or not to criminally charge the company and the fallout that choice could have. Plus, some fast movers catching our attention. Bitcoin tumbling and how Eli Lilly's weight loss success is having some medtech companies tossing and turning.

19:36Don't snooze on that one. You've got the details when Fast Money returns.

19:43This is Fast Money with Melissa Lee right here on CNBC.

19:56Welcome back to Fast Money. Boeing getting a small boost today, up a little over a percent. This despite reports that U.S. prosecutors are urging the DOJ to file criminal charges against the company. The Justice Department last month found Boeing had violated a 2021 deferred prosecution agreement reached after two fatal 737 MAX crashes. It has until July 7th to decide how to proceed. And just a few minutes ago, families of crash victims filed a motion asking a judge to impose a corporate monitor to oversee the company, saying, quote, Boeing presents an ongoing threat to public safety. Now, the stock was up, which sort of a surprise.

20:30You hear the headline that there's going to be criminal charges and you think the worst, but the stock went up. Maybe that's good price action for this. I think it is. I don't think D.C. is going to do anything. I think D.C. has an obligation to make noise about doing something, and that's all they're going to do. And I'm not going to get involved in that. And it's been tragedy after tragedy. So those families deserve at least an audience. But I think it's a case, if you look at the company, the dynamics here are really about max deliveries. And that's the key in terms of the catalyst that we reviewed with Phil last week when he talked about whether it's a CEO change.

21:01It's about max deliveries. That leads to cash flow, which would lead back to the re-rating. I just think you've delayed the cash flow argument that is really the strength of B.A. when they're clicking on all cylinders, and that's obviously whenever. It'll be further delayed. I mean, part of the criminal charges could end up being a fine. They've already paid$2.5 billion, and they could pay who knows how much after this. Without question, but again, it's important to point out, last quarter, for example, revenue in commercial airplanes was$4.6 billion. Okay, why is that interesting? because defense, space, and security was almost$7 billion, and global services was another$5 billion.

21:35So I get it. Commercial airlines, everybody knows Boeing for that. But the other businesses that we talk about all the time are not being valued properly. Now, with that said, I've thought that since$195, that's been wrong. But at a certain point, I think the market wakes up to the fact that, you know, they're completely underestimating the power of Boeing. This company has a QA problem. Let's be clear. Okay, this is going back to 2019. There's been, you know, half a dozen whistleblowers. A few of them have been knocked off recently. It seems like this is kind of a situation where, you know, you may want to pay attention to what the feds are doing here a little bit because this company needs to get their act together.

Read the full transcript

22:09You know, it's interesting. We looked at companies with controversies. And even when they get really, really cheap, what we found the critical factor before you want to buy is seeing like a thorough culture change at the organization. That's very hard to measure. But I think that's what's required here. And it would help if we didn't see headlines like, you know, criminal charges coming from D.C. What were some of the other companies that you studied? Was it like Exxon Valdez? Yeah, we looked at environmental disasters. We looked at Me Too issues. But it was interesting. The common theme was until you saw major culture change.

22:46So not just switching out the CEO, but you had to see the people at the company, the employees actually, acknowledged that the culture had shifted. Like we looked at glass door ratings, I think, and we saw that when when employees said the culture is getting better, that was when you wanted to actually buy the stock. It's fast. That's fascinating stuff. When you think about Meta, obviously, they had that period of really a dead period. I still get back to with Boeing. I think the analyst community is looking at cash flow. They're going to burn$4 billion this year. I mean, this is not a story that is the opposite of why you own this company is because it's a cash flow machine.

23:26So I think there's definitely an overhang. Samita, you're right. I think the fluff factor here for Boeing is probably under pressure for a while, but I bet the street's more concerned with free cash flow. You went to that fancy college. They have a business school. HBS, right? Yes. And they do like studies. There's one company we talk about every quarter. I know that. If not more often, that would be CMG. There's going to be a case study on exactly what you think about that. That company was left for dead when they made the mistakes that they made. And they were able to change the culture and completely reinvent themselves.

24:01That's at the top of my list for a myriad of different reasons. Well, at the time when they were going through those issues and people were getting sick and they had to close down lines, etc., did you think that it was still a buy? We'd have to go back and look at the archives of CNBC's Fast Money. I'm just wondering. But I will tell you this. I was still eating there. I'm sure I did. I mean, probably everybody else other than I thought it was a buy at that point. I mean, this stock, they have done a lot of things right. And the question is, again, I think it's really more focused on the growth model that is CMG, especially internationally, especially loyalty, is part of why it trades at 50 times.

24:36All right. There's a lot more fast money to come. Here's what's coming up next. some medical device makers are sleeping with one eye open as eli lily's weight loss drug finds a new use against sleep apnea that may be a dream for the pharma stock but a nightmare for c-pap companies and sticking with health care one biotech's new drug results sending shares soaring the ceo is here to lay out what it could mean for heart disease and the future of the company You're watching Fast Money live from the Nasdaq market side in Times Square. We're back right after this.

25:16Welcome back to Fast Money. Stocks closing mix to kick off the final week of the first half of the year. The Dow jumping 260 points, the S &P down three tenths of a percent, and semis dragging the Nasdaq lower down more than one percent. Crypto's declined, continuing Bitcoin and Coinbase now both down more than 10 percent since the Fed's last meeting, where they held rates steady once again. Bitcoin falling back below 60 ,000 for the first time since early May. And Eli Lilly higher again today. The company looking to expand its weight loss drug ZepBound to treat sleep apnea after positive trial results.

25:49CPAP makers like ResMed, Inspire Medical and AdaptHealth all dropping on this news. What do you want to trade? Well, I think with Lilly, as much as we've wanted to throw them in the same boat as kind of NVIDIA-like because of what they're doing in the health care sector relative to the innovation to NVIDIA. The fact of the matter is that this is one where they are so far ahead. We talked about the exciting Alzheimer's news last week. And then there's the blocking and tackling in sleep apnea that continues to show these guys are beating up the competition. So I think there's a lot of people out there waiting for a pullback to own this one.

26:21And I would be one. It's amazing that these names continue to trade lower on the same news. It's not like the first time we've heard that ZetBound can help sleep apnea. We've seen it before. Listen, across a swath of industries, we've seen the same news moves the same stocks at different points in time, which I've always found interesting. I'll say this. You know, very quietly, other names are starting. Not nearly the extent of Eli Lilly, but Mark made an all-time high today, for example. Gilead, which we talked about last week. Not a great day today because you open on the highs, close on the lows, but I still think there's room there.

26:51We talked about the move in Sarepta last week. I wouldn't chase it here, but there are other names, ex-Lilly, that I think still makes sense. Yeah, not a valuation metric you use much in big pharma, but price to sales. You know, Lilly's trading nearly 20 times price to sales. It's trading about 16 times. To Guy's point about Merck, okay, that just made a new all-time high, it trades about five or six times sales. You know what I mean? So when you think about, like, it is kind of similar to NVIDIA in a way because investors are getting in front of all the good news that may come in the future. You know what I mean?

27:20So that's what, you know, to me, I think these stories are very similar. So that's an example of large cap value, right? Well, it's not as cheap as other parts of the value spectrum. But it is an example of dividend growth, which I think makes a lot of sense. I worry about health care as a sector, though, because it's gotten very crowded. Generalists are now buying health care stocks for growth and defensive protection. Meanwhile, we're heading into an election. And I know that there is not as much controversy around health care heading into this election. We didn't have a Democratic primary. But I worry that, you know, drug pricing, regulation, all of that is going to start to flow.

27:59And typically you see health care underperform in that, you know, pre-election campaign season. This is also a sector with a high amount of government exposure. A lot of the sales of health care companies come from government contracts. So if everyone's looking at where the government's going to cut spending and fiscal austerity, health care is right there in the hot seat. Coming up, the consumer keeps on trucking. Walmart hitting a fresh all-time high today while its biggest competitor inks a huge e-commerce deal that could shake up the retail space. We'll open up the big box trade next, plus a major heart disease breakthrough, sending alnylam shares to their best day in nearly two years.

28:39The details on this brand-new treatment, what it means for the biotech trade, right after this. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money Podcast. We're back right after this.

28:58Welcome back to Fast Money. Shares of El Nylem surging nearly 35 percent for the stock's best day since August 2022. The biotech company out with positive late stage data on its drug to treat a serious condition affecting the heart's ability to pump blood, slashing patients' risk of death and cardiac incidents by roughly 30 percent. CNBC's Angelica Peebles joins us now for an exclusive interview with the El Nilem CEO Yvonne Greenstreet. Angelica, take it away. Thanks so much, Melissa, and thank you for being here, Yvonne. It's great to see you again. I want to start, of course, with these results.

29:29And you've been saying that you think that these results will make it so that your drug, Butrisiran, becomes the new standard of care for ATTR cardiomyopathy. But I've heard from some people that they want to see the full results before deciding where your drug fits in with Pfizer's drug and Bridge Bio's drug. So tell us how you think your results compare. Yeah, no, thank you, Angela. We could not be more excited about the data that we've generated from HEDEUS-B and what this means for patients. I mean, the results demonstrate a remarkable profile. You touched on vitriceran showing the potential to reduce all-cause mortality in patients with TTR cardiomyopathy by over a third compared to placebo.

30:13These are unprecedented results in the heart failure setting. We also saw statistically significant benefits across all the endpoints, the primary endpoint and all the secondary endpoints, really demonstrating that vitriceran helps patients function better, feel better, and survive longer. You know, this is a home run result for the study. And I think it will demonstrate that vitriceran will become the new standard of care for treating patients with TTR cardiomyopathy. And you're planning to submit the FDA application later this year using the priority review voucher. So what's the timeline once you actually get that application in?

30:53when should we expect to see this drug on the market for this indication? So these are incredibly important data. And clearly, what we want to do is move as expeditiously as possible through the regulatory process to get this medicine to the patients that are in need. Remember, this is a large and rapidly growing market where patients continue to progress. And it opens up a tremendous opportunity for our NADAM. So we're keen to move forward rapidly. and we will be filing the SNDA with the FDA and other global regulatory authorities as well before the end of the year. We've applied for what's called a priority review voucher with the FDA to really expedite the review process.

31:38So we're looking forward to getting this medicine to patients assuming positive regulatory approval as soon as possible next year. And this is a much bigger opportunity than the other drugs that you've had so far. So when do you expect that you might become profitable? So what these data do for us is really unlock the opportunity for substantial top-line growth for our Nylum and value creation. We'd committed to goals around self-sustainable profitability by the end of 2025. And with these data in hand, we believe we have all we need. We have the platform, the pipeline, the financial profile, the talent and the culture in our organization in order to move the company forward and deliver profitability.

32:31So that's what we're absolutely focused on. Yvonne, it's Melissa Lee here at the NASDAQ. On your conference call this morning, you talked about this as being your anchor commercial franchise, which will allow you to pursue therapeutics in other areas. And you mentioned specifically obesity and metabolic disorders. What do you currently have in the pipeline? What do you have on the way in those areas? So one of the hallmarks of our NILUM has been our sustainable, organic innovation engine and our incredibly rich pipeline. This is a very unusual profile in the industry to have both marketed products, a rich pipeline, and a platform that continues to deliver transformative medicines.

33:13And we have a number of really exciting opportunities. A program called Zalbisran in patients with hypertension. We have programs addressing metabolic disorders, obesity, CNS disorders. I think what we really want to do is take the power of our RNAi platform and point it to areas of significant medical need. And I think when we do that, we're able to deliver transformative medicines in the way that we have done with Vutrisran. So we're incredibly excited. And really quick, I was looking today and your market cap is almost now as big as Biogen's after this move today. So how does this change things for you?

33:56Well, what this allows us to do is fulfill our mission, which is about bringing transformative medicines to patients. We've talked about the pipeline and this really gives us the firepower now in order to really expedite progress in our pipeline and bring the power of RNAi to patients. And we couldn't be more excited about what the future holds for the company. Of course, in the near term, we will be focusing on ensuring, as I discussed, that we are able to move through the regulatory processes with Vutrisran to address the needs in this patient group, secure approval and get off to launching this Medsip and bringing this to patients.

34:41Yvonne Greenstreet, thank you so much for joining us today. Back to you, Mel. Thank you so much, Angelica, and our thanks to Yvonne as well. By the way, the company ended the first quarter with about$2.4 billion in cash, so they've got that going for them too. Yeah, without question. I'll say this to throw a little cold water. They extended the trial to 30 to three years, which a lot of people are saying, you know, the reason why they saw the success is because they needed to extend. And again, I'm just pointing that out. So my I guess I bring it up because I don't think you chase here. There are many more chapters left in this story.

35:12If you go back and look at a historic chart of this company, you'll see a lot of pits and a lot of falls. And I think this is one you may want to look to fade instead of continue to own. Just my opinion. The analyst community is so I mean, just absolutely positive. Canaccord said, if they adjusted the model to match expectations by doctors, it would add an additional$404 per share, per share to their price target of$283. Can you imagine? I've never heard of such a thing. It's extraordinary. It's extraordinary where that same community was more cautious, say, on the Sarepta announcement, at least after the stock had priced a lot of it in.

35:53The street came in and they said half the people didn't even change their model or they felt like it had already been priced in after the stock had made that kind of a move. Coming up, we are shopping for some retail names. Walmart hitting all-time highs and Target getting a boost after a new third-party deal. How are traders are handling the moves when Fast Money returns?

36:34Welcome back to Fast Money. Two big box retail moves catching our attention. Shares of Walmart hitting new all-time highs now up more than 30 % this year. Meantime, Target, which has been lagging all year, getting a boost after inking a deal with Shopify to add new and trendier brands to its website, Target up more than 2 % today, but just 5 % so far this year. Would you rather? Oh, it's a favorite game. Why not? Savita, can Savita play this game? That's just not allowed. I can't talk socks. What a shame. Would you rather? Walmart. I'll play it correctly. And I get it. Target, Shopify. How about second derivative?

37:07Savita could opon on would you rather Guy's view or Tim's view of the would you rather? I think I know who would win that game. Now you're slicing and dicing. No, I think, listen, I think Walmart still wins. I get what, I mean, to me it sort of reeks of a little bit of desperation. I get it. Walmart, to me, you stay with that trade. Desperation? this this Shopify deal? No, not necessarily. It depends on the time horizon. The trader in me wants to own Target here and relative to the underperformance. But I think the stock is very range bound, even though at 13 and a half times it's two turns cheap to its historical multiple, because we don't know whether they're trying really hard to get people into the store by giving stuff away really, really cheap or whether they don't even you know, they're concerned about just attracting more traffic, especially in the broader space.

37:53Walmart. If we're playing would you rather, rather. I'd rather go with Shopify here. You know, this is 20 % revenue. I mentioned the company. You did mention it. It's crazy on him. He just got back from vacation. He's forgotten how to buy. Give him a break. I would go with Shopify. I didn't even answer. 20 % revenue growth. And they're likely to kind of hit gap profitability in the next few quarters there. That one should take off. Doesn't this tell you that when you're talking about the consumer not doing too badly and reducing the number of boats? Yep. But they are reducing what they're buying.

38:25Yeah. And they need low price. I mean, there's a value move at grocers and lower price point retailers. I mean, we're underweight consumer staples. And the reason is that we are starting to see a little bit of a trade down. You know, you're no longer buying the high end brands. You're buying the grocery store like the generic. But I still think when you look at the broader picture and you see consumer trends across the board, maybe this is manifesting itself in the lower price point retailers and the lower income consumer group because of higher oil, utilities costs, higher wallet demands from fixed costs.

39:01But I think that when you expand to the broader consumer segment, it still looks pretty healthy. So no reason to sound the alarm bells just yet. All right. Coming up, class is in session. We're laying out the options 101 on Chipotle ahead of the company's big split, how contracts on carnitas will be affected. That's next.

39:30Welcome back to Fast Money. Chipotle shares falling for a third straight day ahead of Wednesday's 50-for-1 stock split, one of the largest in the history of the New York Stock Exchange. While this split will not affect the company's market value, It could change how traders play its options. Mike Coe joins us to break it all down. Hey, Mike. Hi there. So when you have a situation like this, a big stock split, there are two circumstances that can take place that affect options. One of them is more straightforward, one of them a little bit less so. This is one of the straightforward ones. The 50 for one stock split actually means that all you need to do really is multiply the number of contracts that you hold by that stock split number.

40:07So it'll be 50 contracts for every one that you hold right now. and you divide the strike price by that same number. So for example, if you have the 3 ,000 strike, you would divide that by 50. You're going to have the 60 strike option thereafter. And one of the things I would just point out, of course, right after this happens, as you would expect, you're going to multiply all of that open interest by 50 as well. So the volumes are going to go up by quite a lot. But oftentimes, over time, that starts to actually drift a little bit lower because the new lower stock price makes it a little bit more approachable for investors.

40:40What do you think, Dave? It's super annoying because you're going to have all these weird strikes. Because depending upon where the stock trades, you could have like 53, 64 or something like that strike and it makes it really annoying. Right. Because you have to divide. Matt takes that. It's never annoying. I'll say this. Goldman just initiated, I think on the 13th of June, with a$3 ,730 price target. I think now they're high on the street. And again, people will knock Chipotle on valuation, which I understand is concerning. But this has been a juggle. By the way, which has actually pulled back a little recently, so that might be giving you a bit of an opportunity.

41:12It's like the NVIDIA of the restaurant industry. Tim gets on them all the time. I do. I do. They don't have the ingredients you like. They don't have his ingredients. Amsterdam and 73rd Street Store, by the way, you're doing a much better job, people. I will say that if we think that the consumer is under pressure and if we see what's going on with McDonald's and the lower end, it's going to roll up. I think restaurants are hitting a wall. We've seen some of these CPI numbers. They can't charge this much. They're going to have to pull back. And I think that meanwhile, their cost base, their labor specifically, is not getting any cheaper.

41:43So I think they're in a tough spot. I think their best days were COVID and thereafter COVID for a long time. Avocado prices might go up, too, because of security scare in Mexico, apparently. I mean, they're a little more efficient, though. I think that's one of the big stories for the company is that, I mean, they're like who buys NVIDIA and gets efficient in a few years. I think that's the theme right here is think about the companies that are buying the chips and getting more efficient. That's the next buy. Up next, final trades.

42:18Time for the final trade, Tim. Great to have Savita here. Schlumberger, SLB. Savita. I'll go with XLS, Finances. Yes, and thank you, Savita, for joining us. Dan. Yeah, look at the Shopify here. It's had a few bad prints over the last few quarters, but it looks like it's ready to turn. Tim, what are the best words in sports, Tim? Game seven. Game seven tonight, Mel, as you know, in Florida. You'll be you and Savita watching it together. Come on, Cat. Girl night out. Let her see Citigroup in the financial theme. Thanks for watching Fast Mad Money with Jim Cramer starts right now.

42:59All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBCUniversal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

43:34To view the full Fast Money Disclaimer, please visit CNBC.com forward slash Fast Money Disclaimer.

From the publisher

Nvidia notching another day of losses, but the broader markets aren’t taking it too hard. How investors are handling the semi slide. Plus A big jump for one biopharma stock as Alnylam delivers promising new heart drug results. What the CEO had to say about the data, and the impact it could have on the space.

 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Markets Shrug Off Semi Weakness…And One Biopharma Stock Surges After Trial Results 6/24/24CNBC's "Fast Money" · 44 min
Listen in VO